do 1

DO1 (Disperse Orange 1) is an anti-amyloid agent which potently delays both seeded and non-seeded Aβ42 polymerization at substoichiometric concentrations

Lometrexol (LY 264618), an antipurine Antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and Apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1 2 (hSHMT1 2) inhibitor.

Ensartinib (X-396) is a potent and orally active dual ALK MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

1. Gitogenin, tigogenin, and solasodine are novel selective inhibitors of UGT1A4, and do not inhibit the activities of major human CYP isoforms. 2. Gitogenin and (25S)-5α-furastan-3β, 22, 26-triol are the inhibitors of enzyme α-glucosidase with IC50 value

PCC0208009 (IDO-IN-2) is an IDO inhibitor.

Anti-infective agent 9 (compound 1) acts as a Plasmodium falciparum inhibitor, demonstrating an IC 50 of 600 nM. It effectively reduces pyruvate levels and disrupts the TCA cycle within Plasmodium. This compound also exhibits robust metabolic stability and minimal toxicity to human liver cells. Research indicates that the potential targets of Anti-infective agent 9 for inhibiting Plasmodium falciparum do not include 1-deoxy-D-xylulose-5-phosphate synthase (DXPS) [1].